# Semaglutide Exacerbates Stunting in Growth-Impaired Juvenile Male Mice via Reduced Energy Metabolism

**Authors:** Amélie Joly, Lucas Rebiffé, Yves Dusabyinema, Julien Dellinger, Estelle Caillon, Karine Gauthier, François Leulier, Filipe De Vadder

PMC · DOI: 10.1210/jendso/bvaf158 · Journal of the Endocrine Society · 2025-10-10

## TL;DR

Semaglutide worsens growth problems in stunted juvenile male mice by reducing energy metabolism, even without affecting food intake or weight.

## Contribution

The study reveals semaglutide's role in exacerbating growth impairment via metabolic changes in stunted juveniles.

## Key findings

- Semaglutide lowers blood glucose without affecting food intake or weight in normally growing juveniles.
- In growth-stunted mice, semaglutide worsens growth impairment through reduced food intake and catabolic activity.
- GLP-1 signaling interacts with energy metabolism and growth during juvenile development.

## Abstract

Animals rely on linear growth to attain their full adult size. The regulators of this multifactorial process, including environmental and endocrine cues, are still incompletely understood. Notably, GLP-1, glucagon-like peptide 1 (GLP-1) has emerged as a potential player in this process. Here, we employ semaglutide, a pharmaceutical GLP-1R agonist as a tool to mechanistically dissect the interplay between GLP-1 receptor activation, energy metabolism, and linear growth during the juvenile period, independent of its clinical applications. Using a juvenile mouse model, we show that chronic semaglutide treatment lowers blood glucose without affecting food intake or weight gain in juveniles with a normal growth pattern. However, in growth-stunted juveniles, semaglutide treatment exacerbates linear growth impairment through at least 2 concomitant mechanisms: a moderate reduction in food intake, and a decreased catabolic activity incompatible with tissue growth. These data suggest a complex interplay between GLP-1 signaling, energy metabolism, and growth during juvenile development. Overall, these findings highlight the value of semaglutide as a mechanistic tool for understanding how GLP-1 receptor activation modulates growth and metabolism in juveniles, emphasizing the importance of developmental context for interpreting its effects.

## Linked entities

- **Proteins:** GCG (glucagon), GLP1R (glucagon like peptide 1 receptor)
- **Chemicals:** semaglutide (PubChem CID 56843331)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** Gcg (glucagon) [NCBI Gene 14526] {aka GLP-1, Glu, PPG}, Glp1r (glucagon-like peptide 1 receptor) [NCBI Gene 14652] {aka GLP-1R, GLP1Rc}
- **Diseases:** growth impairment (MESH:D006130), weight gain (MESH:D015430)
- **Chemicals:** blood glucose (MESH:D001786)
- **Species:** Mus musculus (house mouse, species) [taxon 10090]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12559790/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12559790/full.md

## References

49 references — full list in the complete paper: https://tomesphere.com/paper/PMC12559790/full.md

---
Source: https://tomesphere.com/paper/PMC12559790